Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

Thomas A. Ciulla, Philip J. Rosenfeld

Research output: Contribution to journalReview article

106 Scopus citations

Abstract

The accumulation of preclinical and clinical evidence implicating VEGF-A in the pathogenesis of neovascular AMD has provided a strong rationale for the development of anti-VEGF agents for this disease. Anti-VEGF therapies have been used successfully in the clinic, encouraging their use in the treatment of other neovascular eye diseases.

Original languageEnglish (US)
Pages (from-to)158-165
Number of pages8
JournalCurrent opinion in ophthalmology
Volume20
Issue number3
DOIs
StatePublished - May 1 2009

Keywords

  • Bevacizumab
  • Macular degeneration
  • Neovascularization
  • Pegaptanib sodium
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

  • Cite this